Affordable Access

deepdyve-link
Publisher Website

Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.

Authors
  • Tsai, Yien Che1
  • Kotiya, Archana2, 3
  • Kiris, Erkan4, 5
  • Yang, Mei6
  • Bavari, Sina4
  • Tessarollo, Lino5
  • Oyler, George A2, 3
  • Weissman, Allan M1
  • 1 Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702; [email protected] [email protected]
  • 2 Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218.
  • 3 Synaptic Research LLC, Halethorpe, MD 21227.
  • 4 US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702.
  • 5 Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702.
  • 6 Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702.
Type
Published Article
Journal
Proceedings of the National Academy of Sciences
Publisher
Proceedings of the National Academy of Sciences
Publication Date
Jun 27, 2017
Volume
114
Issue
26
Identifiers
DOI: 10.1073/pnas.1621076114
PMID: 28584101
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Botulism is characterized by flaccid paralysis, which can be caused by intoxication with any of the seven known serotypes of botulinum neurotoxin (BoNT), all of which disrupt synaptic transmission by endoproteolytic cleavage of SNARE proteins. BoNT serotype A (BoNT/A) has the most prolonged or persistent effects, which can last several months, and exerts its effects by specifically cleaving and inactivating SNAP25. A major factor contributing to the persistence of intoxication is the long half-life of the catalytic light chain, which remains enzymatically active months after entry into cells. Here we report that BoNT/A catalytic light chain binds to, and is a substrate for, the ubiquitin ligase HECTD2. However, the light chain evades proteasomal degradation by the dominant effect of a deubiquitinating enzyme, VCIP135/VCPIP1. This deubiquitinating enzyme binds BoNT/A light chain directly, with the two associating in cells through the C-terminal 77 amino acids of the light chain protease. The development of specific DUB inhibitors, together with inhibitors of BoNT/A proteolytic activity, may be useful for reducing the morbidity and public health costs associated with BoNT/A intoxication and could have potential biodefense implications.

Report this publication

Statistics

Seen <100 times